Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 18.84
MDVN's Cash to Debt is ranked lower than
54% of the 964 Companies
in the Global Biotechnology industry.

( Industry Median: 46.43 vs. MDVN: 18.84 )
Ranked among companies with meaningful Cash to Debt only.
MDVN' s Cash to Debt Range Over the Past 10 Years
Min: 1.1  Med: N/A Max: No Debt
Current: 18.84
Equity to Asset 0.32
MDVN's Equity to Asset is ranked lower than
83% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. MDVN: 0.32 )
Ranked among companies with meaningful Equity to Asset only.
MDVN' s Equity to Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.5 Max: 0.99
Current: 0.32
-0.02
0.99
F-Score: 5
Z-Score: 7.46
M-Score: -2.80
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -25.04
MDVN's Operating margin (%) is ranked higher than
62% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -78.20 vs. MDVN: -25.04 )
Ranked among companies with meaningful Operating margin (%) only.
MDVN' s Operating margin (%) Range Over the Past 10 Years
Min: -510.27  Med: -33.39 Max: 43.96
Current: -25.04
-510.27
43.96
Net-margin (%) -17.24
MDVN's Net-margin (%) is ranked higher than
64% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. MDVN: -17.24 )
Ranked among companies with meaningful Net-margin (%) only.
MDVN' s Net-margin (%) Range Over the Past 10 Years
Min: -496.58  Med: -38.58 Max: 38.91
Current: -17.24
-496.58
38.91
ROE (%) -24.74
MDVN's ROE (%) is ranked higher than
57% of the 878 Companies
in the Global Biotechnology industry.

( Industry Median: -33.45 vs. MDVN: -24.74 )
Ranked among companies with meaningful ROE (%) only.
MDVN' s ROE (%) Range Over the Past 10 Years
Min: -862.65  Med: -91.55 Max: 110.4
Current: -24.74
-862.65
110.4
ROA (%) -13.90
MDVN's ROA (%) is ranked higher than
64% of the 971 Companies
in the Global Biotechnology industry.

( Industry Median: -29.51 vs. MDVN: -13.90 )
Ranked among companies with meaningful ROA (%) only.
MDVN' s ROA (%) Range Over the Past 10 Years
Min: -68.11  Med: -16.91 Max: 42.39
Current: -13.9
-68.11
42.39
ROC (Joel Greenblatt) (%) -133.44
MDVN's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: -372.06 vs. MDVN: -133.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDVN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -201825  Med: -4226.22 Max: 299.97
Current: -133.44
-201825
299.97
Revenue Growth (3Y)(%) 65.20
MDVN's Revenue Growth (3Y)(%) is ranked higher than
91% of the 482 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. MDVN: 65.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDVN' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -100 Max: 113.1
Current: 65.2
0
113.1
» MDVN's 10-Y Financials

Financials (Next Earnings Date: 2017-02-24)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MDVN Guru Trades in Q4 2015

Pioneer Investments 149,693 sh (New)
Paul Tudor Jones 127,060 sh (+882.37%)
Steven Cohen 2,002,700 sh (+22.02%)
Ken Fisher 6,615 sh (+5.00%)
Jim Simons Sold Out
» More
Q1 2016

MDVN Guru Trades in Q1 2016

Joel Greenblatt 327,094 sh (New)
Andreas Halvorsen 707,319 sh (New)
Jim Simons 207,600 sh (New)
Columbia Wanger 1,780,000 sh (New)
Paul Tudor Jones 661,185 sh (+420.37%)
Pioneer Investments 400,496 sh (+167.54%)
Ken Fisher 6,631 sh (+0.24%)
Steven Cohen 291,100 sh (-85.46%)
» More
Q2 2016

MDVN Guru Trades in Q2 2016

Lee Ainslie 52,620 sh (New)
Mario Gabelli 20,200 sh (New)
George Soros 12,800 sh (New)
Eric Mindich 3,082,209 sh (New)
Samuel Isaly 292,900 sh (New)
Jim Simons 852,100 sh (+310.45%)
Steven Cohen 433,200 sh (+48.81%)
Joel Greenblatt 348,619 sh (+6.58%)
Andreas Halvorsen Sold Out
Ken Fisher 6,591 sh (-0.60%)
Pioneer Investments 253,445 sh (-36.72%)
Columbia Wanger 426,668 sh (-76.03%)
Paul Tudor Jones 3,500 sh (-99.47%)
» More
Q3 2016

MDVN Guru Trades in Q3 2016

Pioneer Investments Sold Out
Ken Fisher Sold Out
Columbia Wanger Sold Out
Mario Gabelli Sold Out
Jim Simons Sold Out
Eric Mindich Sold Out
Lee Ainslie Sold Out
George Soros Sold Out
Steven Cohen Sold Out
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
Samuel Isaly Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDVN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:OTCPK:GIKLY, OTCPK:UCBJY, NAS:BMRN, OTCPK:GMXAY, OTCPK:NVZMF, NAS:SGEN, NAS:ALKS, NAS:TSRO, OTCPK:ALIOY, NAS:INCY, NAS:JAZZ, NAS:UTHR, NAS:IONS, NAS:VRTX, NAS:EXEL, NAS:ALNY, NAS:TECH, NYSE:XON, NAS:RARE, NAS:ACAD » details
Traded in other countries:WMD.Germany,
Medivation Inc is a biopharmaceutical company engaged in the development of novel small molecule drugs to treat diseases like Alzheimer's disease and Huntington disease.

Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas. The Company is subject to extensive regulation by the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products.

Top Ranked Articles about Medivation Inc

Pfizer Acquires Medivation Company will pay $14 billion for biopharmaceutical business
Pfizer (NYSE:PFE) reported Monday that it would be acquiring, biopharmaceutical company, Medivation (NASDAQ:MDVN). Pfizer will pay $81.50 per share for a total value of approximately $14 billion. Shares of Medivation opened higher on Monday and gained approximately 20%. Read more...
Weekly Insider Sells: Medivation, JPMorgan Chase, Stryker, Sabre Top insiders make large sales of stock
According to GuruFocus Insider Data, the largest insider sells during the past week were: Medivation Inc. (NASDAQ:MDVN), JPMorgan Chase & Co. (NYSE:JPM), Stryker Corporation (NYSE:SYK) and Sabre Corp. (NASDAQ:SABR). Read more...

Ratios

vs
industry
vs
history
Forward P/E 34.48
MDVN's Forward P/E is ranked lower than
80% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 17.39 vs. MDVN: 34.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 25.27
MDVN's P/B is ranked lower than
94% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: 3.50 vs. MDVN: 25.27 )
Ranked among companies with meaningful P/B only.
MDVN' s P/B Range Over the Past 10 Years
Min: 5.47  Med: 40.14 Max: 2053.33
Current: 25.27
5.47
2053.33
P/S 13.32
MDVN's P/S is ranked lower than
56% of the 695 Companies
in the Global Biotechnology industry.

( Industry Median: 10.41 vs. MDVN: 13.32 )
Ranked among companies with meaningful P/S only.
MDVN' s P/S Range Over the Past 10 Years
Min: 4.43  Med: 14.89 Max: 43.53
Current: 13.32
4.43
43.53
PFCF 45.09
MDVN's PFCF is ranked lower than
65% of the 123 Companies
in the Global Biotechnology industry.

( Industry Median: 24.25 vs. MDVN: 45.09 )
Ranked among companies with meaningful PFCF only.
MDVN' s PFCF Range Over the Past 10 Years
Min: 2.96  Med: 34.26 Max: 260.74
Current: 45.09
2.96
260.74
POCF 41.42
MDVN's POCF is ranked lower than
74% of the 186 Companies
in the Global Biotechnology industry.

( Industry Median: 19.60 vs. MDVN: 41.42 )
Ranked among companies with meaningful POCF only.
MDVN' s POCF Range Over the Past 10 Years
Min: 2.96  Med: 31.42 Max: 206.47
Current: 41.42
2.96
206.47
Current Ratio 4.32
MDVN's Current Ratio is ranked higher than
51% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. MDVN: 4.32 )
Ranked among companies with meaningful Current Ratio only.
MDVN' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.87 Max: 27.3
Current: 4.32
1.46
27.3
Quick Ratio 4.32
MDVN's Quick Ratio is ranked higher than
53% of the 957 Companies
in the Global Biotechnology industry.

( Industry Median: 3.94 vs. MDVN: 4.32 )
Ranked among companies with meaningful Quick Ratio only.
MDVN' s Quick Ratio Range Over the Past 10 Years
Min: 1.46  Med: 3.87 Max: 27.3
Current: 4.32
1.46
27.3
Days Sales Outstanding 80.78
MDVN's Days Sales Outstanding is ranked lower than
64% of the 601 Companies
in the Global Biotechnology industry.

( Industry Median: 61.72 vs. MDVN: 80.78 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDVN' s Days Sales Outstanding Range Over the Past 10 Years
Min: 34.21  Med: 98.56 Max: 151.52
Current: 80.78
34.21
151.52

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -3.10
MDVN's 3-Year Average Share Buyback Ratio is ranked higher than
79% of the 555 Companies
in the Global Biotechnology industry.

( Industry Median: -11.30 vs. MDVN: -3.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDVN' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -199.7  Med: -6.9 Max: 2.2
Current: -3.1
-199.7
2.2

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 11.45
MDVN's Price/Projected FCF is ranked lower than
80% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 2.84 vs. MDVN: 11.45 )
Ranked among companies with meaningful Price/Projected FCF only.
MDVN' s Price/Projected FCF Range Over the Past 10 Years
Min: 2.32  Med: 8.49 Max: 146.5
Current: 11.45
2.32
146.5
Price/Median PS Value 0.89
MDVN's Price/Median PS Value is ranked higher than
54% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. MDVN: 0.89 )
Ranked among companies with meaningful Price/Median PS Value only.
MDVN' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.29  Med: 1.17 Max: 15.75
Current: 0.89
0.29
15.75
Earnings Yield (Greenblatt) (%) -2.00
MDVN's Earnings Yield (Greenblatt) (%) is ranked higher than
66% of the 942 Companies
in the Global Biotechnology industry.

( Industry Median: -8.50 vs. MDVN: -2.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDVN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2  Med: 3.3 Max: 8.3
Current: -2
-2
8.3

More Statistics

Revenue (TTM) (Mil) $1,027
EPS (TTM) $ -1.10
Short Percentage of Float2.49%
52-Week Range $26.41 - 81.48
Shares Outstanding (Mil)165.93

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 917 1,208 1,429 1,676
EPS ($) 1.47 2.28 3.10 3.92
EPS w/o NRI ($) 1.47 2.28 3.10 3.92
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MDVN

Headlines

Articles On GuruFocus.com
How a 15% Decline Is a Gift to Income Investors Nov 21 2016 
Pfizer Refuses to Go the Spinoff Route Oct 17 2016 
Gilead’s Patience Is Wearing Investors' Patience Thin Oct 10 2016 
Steven Cohen Increases Position in Dynavax Oct 07 2016 
Sanofi Sues Merck Over Patent Infringement Sep 20 2016 
Pfizer: Hospira Is Future; Xtandi Is Today’s Meal Sep 19 2016 
Sanofi in a State of Suspended Animation Until Boehringer Ingelheim Swap Sep 19 2016 
Pfizer Acquires Medivation Aug 22 2016 
Sam Isaly's Top Investments of the Year Aug 01 2016 
Sam Isaly Swaps 3 Health Care Stocks in Second Quarter Jul 29 2016 

More From Other Websites
Is ONEOK, Inc. (OKE) Going to Burn You? Dec 05 2016
The Pfizer-Medivation Deal, Completed in 3Q16 Nov 29 2016
How a 15% Decline Is a Gift to Income Investors Nov 21 2016
Bristol Myers Squibb Co. (BMY), Alkermes Plc (ALKS) & More: How Opus Point’s Bet on Healthcare... Nov 18 2016
After FDA Approval, Merck Posts Better-Than-Expected Earnings Oct 25 2016
Ariad Could Follow Gilead's — Or Mylan's — Route In Drug Price Battle Oct 24 2016
Gilead's Patience Is Wearing Investors' Patience Thin Oct 10 2016
Tesaro Bolts On Ovarian Cancer Win Vs. AstraZeneca, AbbVie Oct 10 2016
New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly... Oct 09 2016
Biotech Mergers Run the Show: 5 Small-Cap Stocks for Q4 Oct 04 2016
Key FDA Decisions and Trial Results Expected in October Oct 04 2016
Vigorous M&A Activity Signals Economic Health Oct 03 2016
A Look at the Pfizer-Medivation Deal Sep 29 2016
Pfizer Completes Acquisition of Medivation Sep 28 2016
MEDIVATION, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of... Sep 28 2016
Pfizer Completes Acquisition of Medivation Sep 28 2016
Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 Sep 28 2016
Medivation Highlights New Data From Differentiated Oncology Portfolio at ESMO 2016 Sep 28 2016
Blog Coverage US Pharma Giant Pfizer to Whole as one Complete Unit Sep 27 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)